Emergent BioSolutions Inc.
EBSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeEmergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States,. The company carries a $393.7M market cap, placing it firmly in the small-cap category. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Market Cap
$393.7M
Beta
2.34
P/E (TTM)
—
P/E (Fwd)
2.55
EPS (TTM)
$-0.19
EPS (Fwd)
$2.99
ROE
-1.6%
ROA
3.4%
Cash
$160.3M
Total Debt
$584.6M
Free CF
$256.2M
52W Change
10.1%
Annual Financials
Cash vs Debt
On the balance sheet, EBS has $160.3M in cash with $584.6M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $256.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -1.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.4% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $1.64B (2021) to $705.2M (2025), a 57% decline worth watching.
Emergent BioSolutions Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. No single metric tells the full story. Reviewing EBS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.